Evaluation of SONA’s Gold Nanoparticle-Mediated Photothermal Therapy in Combination with Intralesional Immune Modulation as a novel Immuno-Oncology strategy for Colorectal Cancers, Skin Cancers and Breast Cancers
Dr Carman Giacomantonio, MD, MSc., FRCSC
Dr. Carman Giacomantonio is a surgeon and surgical oncologist at the QEII Health Sciences Center and a professor of surgery at Dalhousie University. He is also the Chief of Surgical Services at CEHHA in Truro, NS. Dr. Giacomantonio’s research interests include cancer metastases, specifically breast, melanoma, and colorectal cancer. He has conducted several studies on the impact of surgical procedures on the tumor microenvironment and subsequent development of cancer metastases, as well as ways to mitigate this risk through targeted therapies.
Dr. Giacomantonio has published several notable papers, including “Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model” and “Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A”. He has also contributed to guidelines on the use of cytoreductive surgery and HIPEC in patients with peritoneal surface malignancy.
Dr. Giacomantonio serves on several advisory boards, including the Medical Advisory Board for Colorectal Cancer Canada.
Overall, Dr. Carman Giacomantonio is a highly accomplished surgeon and researcher with a focus on cancer metastases and targeted therapies. His contributions to the field have been significant, and he continues to serve on advisory boards and conduct research to improve cancer treatment and outcomes.
Dr. Carman Giacomantonio is serving as PI for Sona’s study. The study aims to evaluate the ability of the therapy to act as a catalyst to generate immune responses and provide data that will form part of any future regulatory submissions in support of the development of its Targeted Hyperthermia Therapy. The study is innovative and marks the beginning of Sona delivering on the ‘mountain of data’ they committed to developing in support of their planned regulatory submissions for human clinical trial approvals. The results of the study are anticipated to provide valuable insights into the development of Targeted Hyperthermia Therapy, a photothermal cancer therapy that uses therapeutic heat to treat solid cancer tumors. The use of nanotechnology in cancer therapy is a rapidly growing field, and the study is an exciting development in the search for more effective and targeted cancer treatments.
Barry Kennedy, PhD
Barry Kennedy is a dedicated scientist with a passion for advancing human health and well-being. With two decades of experience spanning academic and industrial laboratories, he has devoted his career to pushing the boundaries of scientific knowledge. Currently, he holds the position of Principal Research Scientist in the Giacomantonio Immuno-Oncology Research Laboratory in the Department of Pathology at Dalhousie University. In this role, he plays a vital part in advancing research while fostering a culture of innovation within the institution. His work integrates research, translational efforts, and strategic collaborations with the biotechnology sector.
Dr. Kennedy’s science commenced with a Ph.D. in the Department of Biochemistry and Molecular Biology at Dalhousie University, where he investigated aberrant lipid trafficking and mitochondrial dysfunction during neurodegeneration. Building upon this foundation, he embarked on postdoctoral fellowships that explored deeper into the strategic manipulation of mitochondrial metabolism to enhance the efficacy of oncolytic viral immunotherapies.
As a Research Scientist and Biomarker Lead at IMV, a clinical-stage biopharmaceutical company specializing in a novel class of cancer vaccines, Dr. Kennedy provided scientific leadership, developed standard operating procedures, and engaged in strategic discussions with thought leaders. He collaborated closely with preclinical development teams to craft robust biomarker strategies and partnered with the clinical operations team to ensure scientific alignment with operational objectives during trials.
Dr. Kennedy has secured significant funding through grants and strategic partnerships with the biotechnology sector. This funding has facilitated the publication of over 30 peer-reviewed papers and garnered recognition at local, national, and international conferences. His passion for science is solid, and he is committed to leveraging his skills and expertise to make a meaningful impact on human health and well-being.
We hypothesize that the combined utilization of GNRs and precise immune modulation will lead to enhanced immune activation and potent anti- tumor responses in colorectal cancer, breast cancer, and melanoma mouse models.
Immune Reprogramming through Tumor Neo-antigen
Objective 1: Investigating i.p. Tumor Site Immune Response and Therapeutic Impact
Conducting an in-depth exploration of the immune response dynamics and therapeutic implications, specifically within the i.p. tumor site
Objective 2: Unraveling s.c. Tumor Antigen Site Immune Enhancement with IL-2
Uncover the potential of GNPs and NIR treatment, complemented by the inclusion of IL-2, in enhancing immune responses within this distinct microenvironment
Objective 3: Unveiling Molecular Pathways, Immune Checkpoint Dynamics, and Systemic Response to Tumors after Neo-Antigen Relocation Therapy
Thoroughly investigate molecular pathways and immune checkpoint dynamics at both i.p. and s.c. sites to uncover factors driving distinct therapeutic effects from combined treatments. Study systemic response post neo-antigen relocation therapy for broader insights into immune interactions beyond localized sites.
Evaluating Tumor Response and Immune Modulation in Subcutaneous Tumor Models after Diverse Immunotherapeutic Interventions
Objective 1: Assessing Diverse Interventions in Tumor Models
Evaluate the impact of GNPs, IL-2, and TLR agonists (TLR4, TLR7, TLR9) individually and in combinations on tumor growth, metastasis, and local/systemic immune response in 4T1 breast cancer and B16 melanoma mouse models.
Objective 2: Comprehensive Immune Analysis in Tumor Models
Analyze localized and systemic immune responses from treatments in tumor microenvironment, draining lymph nodes, spleen, and peripheral blood. Profile immune cells, cytokines, and systemic effects associated with interventions in 4T1 breast cancer and B16 melanoma mouse models.
Objective 3: Probing Molecular Pathways in Tumor Models
Investigate molecular mechanisms governing therapeutic effects, including immune cell activation, gene expression patterns, and genomic traits. Uncover intricate pathways driving observed outcomes from diverse treatments in 4T1 breast cancer and B16 melanoma mouse models.
Additional Research Links
2023 | Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG
D Vidovic, LK Helyer, S Pasternak, CA Giacomantonio
Frontiers in Oncology 13, 1160269
2022 | Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review
A Drohan, D Vidovic, PJ Barnes, CA Giacomantonio, LK Helyer
Frontiers in Oncology 12, 877014
2021 | Case report: combined intra-lesional IL-2 and topical imiquimod safely and effectively clears multi-focal, high grade cutaneous squamous cell cancer in a combined liver and …
D Vidovic, GA Simms, S Pasternak, M Walsh, K Peltekian, J Stein, …
Frontiers in Immunology 12, 678028
McConnell YJ, Giacomantonio CA.
Malignant triton tumors _ complete surgical resection and adjuvant radiotherapy associated with improved survival.
J Surg Oncol. 2012 Jul 1:106(1):51-6.
Tarrant, J.P., Walsh, M.J., Blanchard, M.C., Lee, T.D.G., Hoskin, D.W., and Giacomantonio, C.A.
Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A.
Int. J. Oncol., 2004; 25: 1693-1699.